In demyelinating diseases such as multiple sclerosis (MS), an imbalance between the demyelination and remyelination rates underlies the degenerative processes. Microglial activation is observed in demyelinating lesions; however, the molecular mechanism responsible for the homeostatic/environmental change remains elusive. We previously found that cystatin F (CysF), a cysteine protease inhibitor, is selectively expressed in microglia only in actively demyelinating/remyelinating lesions but ceases expression in chronic lesions, suggesting its role in remyelination. Here, we report the 
permissive to remyelination to one that is nonpermissive. The significance of the environment surrounding oligodendrocytes and OPCs has been gaining increased attention due to the identification of factors such as PSA-NCAM (Charles et al., 2002) and hyaluronan (Back et al., 2005 ) that inhibit remyelination.
Microglia are well known to act as innate resident immune cells and active surveyors of the extracellular environment in the central nervous system (CNS) (Arnoux & Audinat, 2015; Kreutzberg, 1996; Ransohoff & Perry, 2009; Schafer et al., 2012; Shemer, Shemer, Erny, Jung, & Prinz. 2015) . During the remyelination process, microglia play a critical role in myelin removal (Kotter, Kotter, Li, Zhao, & Franklin, 2006) . However, it has been reported that microglial paralysis can repress EAE (Heppner et al., 2005) . Moreover, it is known that macrophages laden with myelin are anti-inflammatory in MS (Boven et al., 2006) , and that myelin-phagocytosing macrophages in the CNS and the peripheral nervous system (PNS) show both inflammatory and antiinflammatory responses (van Rossum, Hilbert, Strassenburg, Hanisch, & Br€ uck, 2008) . Also, CCR5 expression on microglia is associated with early remyelination (Trebst, K€ onig, Ransohoff, Br€ uck, & Stangel, 2008) .
Thus, the comprehensive role of microglia in remyelination remains elusive.
We have utilized the hemizygous proteolipid protein 1 (Plp1) transgenic mouse strain, 4e (Plp 4e/-), which has two extra Plp1 genes, and demonstrated its use as an ideal model for studying demyelination and remyelination (Kagawa et al., 1994; Shimizu et al., 2013) . The use of appropriate animal models is essential for studying the mechanisms underlying these environmental changes. Transgenic Plp 4e/-mice appear to undergo normal myelination with no signs of myelin degeneration until two months of age. However, at two months of age they show spontaneous demyelination accompanied by remyelination in the early phase but which terminates after 6 months of age (during the chronic demyelinating phase), resulting in the appearance of chronic lesions throughout the CNS and naked axons (Kagawa et al., 1994) .
During the demyelinating phase, Plp 4e/-mice do not show T-cell infiltration in the lesions. However, an upregulation of IL-1b and TNF-a mRNA was detected, although their protein levels were below detection (unpublished data). While the oligodendrocytes extended processes parallel with the axons, they failed to form myelin structure, indicative of the presence of premyelinating oligodendrocytes (Ma, Matsumoto, Tanaka, Takebayashi, & Ikenaka, 2006) . The presence of premyelinating oligodendrocytes in chronic demyelinated lesions is also associated with MS (Chang et al., 2002) . Thus, we used the Plp 4e/-mouse as a model to study the mechanisms behind remyelination impairment in chronic lesions.
In a previous study, we performed cDNA microarray analysis using Plp 4e/-mice to search for changes in gene expression (Ma, Tanaka, Yamada, & Ikenaka, 2007) . We identified that microglial CysF expression is indicative of ongoing demyelination/remyelination and the absence of CysF expression indicates the cessation of remyelination in demyelinating lesions (Ma et al., 2011) . Cystatin F is a cysteine protease inhibitor expressed selectively in immune cells (Halfon et al., 1998) . The official symbol of cystatin F is Cst7, also known as CMAP (cystatin-like metastasis-associated protein) and leukocystatin; in this study we will use CysF for the abbreviation of cystatin F. A major target of CysF is the lysosomal cysteine protease cathepsin C (Hamilton, Colbert, Schuettelkopf, & Watts, 2008) , which is known to regulate the activation of effector granule-associated serine proteases in T cells, natural killer cells, neutrophils and mast cells that are related to immune and inflammatory processes (Adkison, Raptis, Kelley, & Pham, 2002; Eyles, Roberts, Metcalf, & Wicks, 2006) . The official symbol of cathepsin C is Ctsc, also known as DPP1, DPPI, and AI047818, but here we will use CatC as the abbreviation for cathepsin C. In our previous study, CysF was shown to be expressed by activated microglia primarily in the white matter during acute demyelination and active remyelination, but its expression was terminated during the chronic demyelinating phase (at 8 months of age) except in regions where the myelin remained intact. Moreover, in MS, CysF expression is limited to the remyelinating plaques but not found within the chronic lesions, consistent with the pattern in the Plp 4e/-mouse model of demyelinating disease (Ma et al., 2011) .
In this study, we investigated the roles of CatC and CysF in Plp 4e/-mice. We generated novel transgenic mouse lines in which the levels of CatC or CysF can be manipulated by use of the Flexible Accelerated STOP Tetracycline Operator knockin (FAST) system (Tanaka et al., 2010) . We show that the balance between CatC and CysF expression in the brain controls remyelination in chronic demyelinating lesions.
These results should aid in the development of novel and effective treatments for MS and other demyelinating diseases.
| MATERIALS A ND METHODS

| Ethics statement
All animal procedures were conducted in accordance with the guidelines described by the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and approved by the National Institute for Physiological Sciences Animal Care and Use Committee. The generation of STOP-tetO mice was in accordance with the guidelines set by the animal welfare committee and the ethics committee of Niigata University.
| Generation of STOP-tetO knockin mice
The targeting vector containing the 10 kb 3 0 -homology arm, Neo STOP-tetO cassette, 1.8 kb 5 0 -homology arm, and diphtheria toxin A subunit (DTA) was designed to insert the Neo STOP-tetO cassette just upstream of the cathepsin C or cystatin F translation initiation site (Tanaka et al., 2010) . The C57BL/6N ES cell line RENKA (Mishina & Sakimura, 2007) 
| Animals
We used the hemizygous Plp1 transgenic mouse strain 4e (Plp ) (both C57BL/6N background) and Iba1-tTA mouse line 75 (initial BDF1 background backcrossed to C57BL/6 background; Tanaka et al., 2012) . Genotyping of the Plp 4e/-and Iba1-tTA mice was performed as described previously (Kagawa et al., 1994; Tanaka et al., 2012 
| Preparation of primary cultured microglia and immunocytochemistry
The previously reported method for rat primary microglial cultures (Sawada, Suzumura, Yamamoto, & Marunouchi, 1990; Suzumura, Mezitis, Gonatas, & Silberberg, 1987) was applied to mouse. Microglial cells were harvested from primary mixed glial cell cultures prepared from neonatal CD1 mouse brains (Charles River, Kanagawa, Japan) . In brief, after carefully removing the meninges, neonatal brain was dissociated by gentle pipetting. The cell suspension was plated in 75 cm 2 culture flasks (Falcon 3024: Becton-Dickinson Japan, Tokyo, Japan) at a density of five brains per 12 flasks in 10 ml Eagle's minimum essential medium supplemented with 10% fetal bovine serum, 5 mg/ml bovine insulin, and 0.2% glucose. Microglial cells were isolated on days 14-21 on a rotary shaker as previously reported (Suzumura et al., 1987) and cultured in the medium for two days. Two days after microglial separation, immunocytochemistry was performed as described previously (Shimizu et al., 2013) . The following primary antibodies were used: rabbit anti-Iba1 polyclonal antibody (1:1000; Wako, Osaka, Japan), rabbit anti-cystatin F polyclonal antibody (1:1000; Gift from Prof. Colin
Watts, University of Dundee), mouse anti-cathepsin C polyclonal antibody (1:100; R&D system, Minneapolis, MN).
2.6 | Cathepsin C activity assay 
| In Situ hybridization and immunohistochemistry
Mice were perfused intracardially through the left ventricle with 4% paraformaldehyde (PFA), and brains and spinal cords were dissected out. The tissues were postfixed with 4% PFA overnight and cryoprotected with 20% sucrose-PBS buffer overnight and frozen. Cryosections were prepared at 20 lm thickness with a cryostat and used for in situ hybridization (ISH) and immunohistochemistry (IHC). ISH was performed as described (Ma et al., 2011) . The following plasmids containing mouse cDNA were used to generate the ISH probes: c-fms (Ma et al., 2011) , cystatin F (Ma et al., 2011) , and cathepsin C (nucleotides 193-1324 corresponding to NM_009982.4).
Immunohistochemistry was performed as described (Shimizu et al., 2013) . The following primary antibodies were used: rabbit anti-Iba1 polyclonal antibody (1:1000; Wako, Osaka, Japan), rabbit anti-cystatin captured using an Olympus digital camera system (DP70) in combination with a microscope (Olympus BX51).
| Image analysis and statistical analyses
The myelin-stained region (area of CNPase labelling) was quantified by measuring the density using the Image J program for densitometric analysis (National Institutes of Health, Bethesda, MD, USA). Data were expressed as the mean 6 S.E.M. Significance was assessed by an unpaired two-tailed Student's t-test using GraphPad Prism version 5.0b
statistics software (GraphPad Software, Inc., La Jolla, CA, USA).
p-values of less than 0.05 were considered significant.
| Electron microscopy
Mice were perfused intracardially through the left ventricle with a fixative containing 2.5% (v/v) glutaraldehyde and 2.0% (w/v) PFA in 0.1 M cacodylate buffer (pH 7.4). Brains were dissected and immersed in the same fixative for a couple of days at 48C, then 0.5 mm-thick para-sagittal slices were cut with a razor blade and 2 mm 3 1.5 mm blocks from the cerebellar lobes were processed for electron microscopy. After osmification in a 1% (w/v) osmium tetroxide solution for 2 h at 48C, the specimens were dehydrated through a graded alcohol series and embedded in Epon 812
(TAAB Laboratories, Aldermaston, UK). Semi-thin sections at 1 lm thickness were collected, stained with 0.5% (w/v) Toluidine blue in 0.1 M PB and imaged with a light microscope (Olympus) equipped with an autodigitizer to generate "virtual slides" (NanoZoomer-RS, Hamamatsu Photonics). For whole area analysis of the same specimens by EM, ultrathin sections were cut on an ultramicrotome (Ultracut UCT, Leica, Germany) without trimming, collected on platinum-coated glass slides, stained with uranyl acetate and lead citrate and imaged with a scanning electron microscope equipped with a back-scattered electron beam detector (SU8010, Hitachi, Japan) at 1.5 KV accelerating voltage. From each section, a digitized image with an area of about 200 lm by 300 lm was captured at a resolution of 24.8 nm/pixel.
| R E S U LTS
3.1 | Spatial and temporal expression pattern differences of cathepsin C and cystatin F between active remyelinating and chronic demyelinated phases
In Plp 4e/-mice, while spontaneous myelin degeneration starts at 2 months of age, rapid axon remyelination occurs until 6 months of age.
After 6 months, the maturation of oligodendrocytes is arrested and remyelination ceases (Ma et al., 2006; Shimizu et al., 2013) . We previously found that CysF gene expression was greatly reduced at 8 months of age compared to 4 and 6 months in Plp 4e/-mice (Ma et al., 2007 (Ma et al., , 2011 . It has been reported that a major target of CysF is a cysteine protease, CatC (Hamilton et al., 2008) . Thus, we examined CatC mRNA expression in Plp 4e/-mice at different time points. At the onset of myelin degeneration in Plp 4e/-mice at 2 months of age, CysF mRNA expression began ( Figure 1A ,C), however, CatC mRNA was not yet detected ( Figure 1B,D) . During the subsequent demyelination/remyelination phase at 4 months of age, the CysF expression pattern was similar to that of CatC ( Figure 1E -H). At 7 months of age, the expression of both CysF and CatC was reduced. However, the reduction in CysF mRNA expression seemed more rapid than that of CatC ( Figure 1I-N) ; thus, in some regions, CysF expression had mostly disappeared ( Figure 1M ) while CatC expression continued ( Figure 1N ). From these results we concluded that CysF expression starts earlier than CatC, when demyelination is ongoing, but terminates its expression earlier than CatC in Plp 4e/-mice.
CysF and CatC were shown to be lysosomal proteins in a cell line of human leukemic monocyte lymphoma, U937, and in hypoxic-ischemic brains (Hamilton et al., 2008; Koike et al., 2013 Figure 1O ), suggesting that CatC activity can be inhibited by CysF in microglia.
| Generation of STOP-tetO knockin mice to manipulate CatC and CysF gene expression
To study the role of CatC and CysF in demyelinating diseases, we generated transgenic mouse lines in which CatC or CysF expression can be manipulated using the FAST system we established previously (Tanaka et al., 2010) . We crossed those mouse strains with 3.3 | Generation of cathepsin C or cystatin F overexpression in mouse microglia using the FAST system
Since we found that CatC and CysF colocalized within microglia ( Figure   1O ), we generated microglia-selective CatC and CysF overexpressing mice as a gain-of-function study. :: Iba1-tTA) was achieved by crossing respective STOP-tetO knockin mice with the microglia-selective tTA-expressing line Iba1-tTA.
To confirm the tTA-mediated CysF overexpression, brains from postnatal day 21 (P21) mice were examined. Iba1-tTA mice did not show any CysF expression ( Figure 3A ,E), whereas CysFOE mice showed abundant CysF mRNA ( Figure 3B ) and protein ( Figure 3F ) without increasing the number of microglia ( Figure 3C,D) . In these mice, all
CysF mRNA-positive cells were also Iba1-positive ([ Figure 3G ).
CysF is known to be glycosylated (Ni et al., 1998) , and both the monomeric and slowly migrating glycosylated forms were detected ( Figure 3I ), consistent with a report by Hamilton et al. (Hamilton et al., 2008) . However, the ratio of CysF mRNA and Iba1 double-positive cells to the total number of Iba1-positive cells in 11-week-old CysFOE
] ' 50%; Figure 3H ) was greatly decreased compared to that in P21 mice ( Figure 3G ). Thus, either CysF expression driven by the tTA-tetO system was shut down, or the level of CysF mRNA derived from this system was below the limit of detection by ISH through an unknown mechanism.
In wild type mice, CatC is expressed mainly in the CA2 region of the hippocampus and choroid plexus (Figure 2A,B) . In CatCOE mice, CatC-overexpressing Iba1-positive cells were observed throughout the entire brain (about 70% of cells were CatC 1 Iba1
1
; Figure 4A -C). The enzymatic activity of CatC in the brain of CatCOE mice was examined using a specific substrate (H-Gly-Arg-b-naphthylamide) and was found to be greatly increased compared to controls, indicating that induced CatC protein has enzymatic activity ( Figure 4D ).
From these crosses, we succeeded in obtaining CysFKD, CatCKD and CatCOE mice. Unfortunately, the CysFOE mice generated using this recombination system did not show the gene expression expected to be derived from the tTA-tetO system. Therefore, the use of the CysFOE mice was omitted from this study. 
| Phenotypic evaluation in mice with CysF or CatC genetic manipulations
In these mice in which we manipulated the expression of microglial genes, it was necessary to evaluate the differences between WT and CysFKD, CatCKD or CatCOE mice during adult stages. None of these transgenic lines showed any overt phenotypes or clinical symptoms, therefore we examined the specific microglial morphology in these mice. Given that adult mice are needed to evaluate demyelinated lesions, we used two-month-old mice for this experiment. In wild type mice, the microglial morphology, as detected by Iba-1 IHC, showed a normal "resting" shape, i.e. small cell body and numerous very thin and highly branched processes ( Figure 5A ). In CatCKD mice, the morphology of the microglia remained in the resting stage, similar to wild type mice ( Figure 5A ,B). In contrast, in both the CysFKD ( Figure 5C ) and CatCOE mice ( Figure 5D ), the "activated" microglia phenotype was Figure 6D , and was measured as described in the Materials and Methods.
CysFKD::Plp 4e/-mice showed more severe myelin loss compared to control mice ( Figure 6A-C) . The percentage of the CNPase-stained area in a single cerebellar folium from CysFKD::Plp 4e/-mice was significantly decreased (5.15 6 0.86%, n 5 6) compared to the control group (10.63 6 0.49%, n 5 5; Figure 6C ). We also examined the olfactory tracts and found that 4-month-old CysFKD::Plp 4e/-mice also showed a 3.6 | CatC overexpression also enhanced demyelination in Plp 4e/-mice
Given that the increase in CatC activity resulting from CysF deprivation exacerbated demyelination ( Figures 1I-N Figure 7A,B) . We quantified the CNPase-stained area in a single cerebellar folium in parasagittal sections, as shown in Figure 6D . The percentage of the CNPase-stained area in the CatCOE::Plp 4e/-mice was significantly decreased (5.10 6 0.36%, n 5 8) compared to the control group (7.86 6 0.64%, n 5 4; Figure 7C ). We also examined the olfactory tracts and found that, at 2.5 months of age, CatCOE::Plp 4e/-mice showed a significant decrease (43.42 6 3.09%, n 58) compared to control Plp 4e/-mice (63.65 6 2.54%, n 5 4). Furthermore, we performed electron microscopic (EM) imaging of the cerebellum from CatCOE::Plp 4e/-and Plp 4e/-mice ( Figure 7D ,E). We observed massive myelin loss in CatCOE::Plp 4e/-mice at 2.5 months of age, while myelin was maintained in Plp 4e/-mice of the same age ( Figure 7A,B) . This is consistent with the results obtained using the CysFKD mice. These results indicate that the balance between CatC and CysF is very important for maintaining myelin regeneration during the early phase of demyelinating diseases. The percentage of the CNPase-stained areas in CatCKD::Plp 4e/-mice (14.11 6 1.25%, n 5 9) was significantly higher than in CatC STOP-tetO/1
::
Plp 4e/-mice (7.90 6 2.97%, n 5 3) at 8 months of age ( Figure 8F ), while no significant differences were found at 6 months of age ( Figure 8E ; n 5 3 mice each per group). We also examined the olfactory tracts and found that CatCKD::Plp 4e/-mice at 8 months of age showed a significantly higher percentage of stained area (47.62 6 5.27%, n5 9) compared to control CatC STOP-tetO/1 ::Plp 4e/-mice (21.80 6 1.37%, n 5 3). To confirm this result, we performed EM imaging of these mice. More myelinated axons were observed in CatCKD::Plp 4e/-mice ( Figure 8H ) compared to controls ( Figure 8G ). We also quantified the number of myelinated axons for each diameter range. We found that CatCKD::Plp 4e/-mice at 8 months of age had an increased number of myelinated axons with larger diameters (myelinated axon diameter between 1 and 3.5 lm) compared to WT 
| DISCUSSION
In chronic MS lesions, the remyelination process is impaired resulting in demyelinated lesions (Chang et al., 2002; Kuhlmann et al., 2008; Noseworthy, 1999) . The most crucial question is what factors govern the oligodendrocyte precursor recruitment and oligodendrocyte differentiation phases of remyelination, and whether misregulation of any of these factors can account for remyelination failure. Previous studies have identified several pathways with the potential to have therapeutic efficacy (Fancy et al., 2010) . We had previously reported that microglia express CysF only during the active remyelinating stage (at 4-6 months) and that downregulation of CysF expression indicates the cessation of remyelination in demyelinating regions (Ma et al., 2011) . CysF is a specific inhibitor of CatC, and CatC mediates the generation of pro-inflammatory cytokines such as tumor necrosis factor-a (TNF-a) which is highly toxic to oligodendrocytes, and interleukin 1-b (IL-1b) a remyelination promoting factor (Adkison et al., 2002; Hamilton et al., 2008; Mason, Suzuki, Chaplin, & Matsushima, 2001; McLaurin et al., 1995; Ye & D'Ercole, 1999 (Hanisch, 2002; Kotter et al, 2006; Lampron et al., 2015; Stollg & Jander, 1999) . Activated microglia have been found to persist in chronic demyelinating lesions (Tanuma, Sakuma, Sasaki, & Matsumoto, 2006; Taupin et al., 1997) . It seems that changes in the normal levels of CatC or CysF beyond physiological levels cause a disturbance in the brain homeostasis and the activation of microglia.
It is possible that CatC and CysF could send crucial signals that alert the CNS to prepare microglia which can respond to any type of CNS disturbance.
In Plp 4e/-mice, CysF and CatC had similar expression patterns during the active remyelinating phase at 4 months of age, shown in Figure   1E -H. However, CysF was found to be expressed earlier than CatC during active demyelination and remyelination ( Figure 1A-D) when it not typically proceed uniformly and shows some regional variation, even among individuals, the demyelination we observed in the cerebellum and olfactory tracts was relatively constant. Therefore, we chose these regions for our statistical analysis.
During the late phase of chronic demyelinating disease, CatC was found to dominate CysF and full activation of microglia is expected.
This could cause impaired myelin regeneration and the appearance of naked axons in the Plp 4e/-mice (Kagawa et al., 1994) . We found that 
